Inhibition of PKC-δ reduce rhabdomyolysis-induced acute kidney injury

J Cell Mol Med. 2022 Jun;26(11):3243-3253. doi: 10.1111/jcmm.17331. Epub 2022 May 2.

Abstract

Despite extensive research, the mechanisms underlying rhabdomyolysis-induced acute kidney injury (AKI) remain largely elusive. In this study, we established both cell and murine models of rhabdomyolysis-induced AKI by using myoglobin and glycerin, respectively, and provided evidence that protein kinase Cδ (PKC-δ) was activated in both models and subsequently promoted cell apoptosis. Moreover, we found that this detrimental effect of PKC-δ activation can be reversed by its pharmaceutical inhibitor rottlerin. Furthermore, we detected and confirmed the existence of PKC-δ-mediated myoglobin-induced cell apoptosis and the expression of TNF-α and IL1-β via regulation of the p38MAPK and ERK1/2 signalling pathways. In summary, our research revealed the role of PKC-δ in renal cell apoptosis and suggests that PKC-δ is a viable therapeutic target for rhabdomyolysis-induced AKI.

Keywords: AKI; ERK1/2; PKC-δ; apoptosis; p38.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury* / etiology
  • Acute Kidney Injury* / metabolism
  • Animals
  • Apoptosis
  • Mice
  • Myoglobin
  • Protein Kinase C-delta / metabolism*
  • Rhabdomyolysis* / complications

Substances

  • Myoglobin
  • Prkcd protein, mouse
  • Protein Kinase C-delta